Tag: antisense and rnai therapeutics market trends

  • Antisense & RNAi Therapeutics Market Valuation Expected To Reach $3.11 Billion By 2029, Growing At A Rate Of 12.8%

    Antisense & RNAi Therapeutics Market Valuation Expected To Reach $3.11 Billion By 2029, Growing At A Rate Of 12.8%

    Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

    How Has the Antisense & RNAi Therapeutics Market Growth Performance Trended Historically, And What Lies Ahead?

    The market size of antisense and RNAi therapeutics has experienced a swift upsurge in recent times, with projections showing an increase from $1.75 billion in 2024 to $1.93 billion in 2025, indicating a compound annual growth rate (CAGR) of 10.2%. This augmentation during the historical period can be ascribed to an upswing in funding, technological advancements, and an increase in health care spending, alongside a fast-paced growth in the aged population and the economic expansion in budding markets.

    In the coming years, the antisense & RNAi therapeutics market is projected to experience substantial growth, expanding to $3.11 billion in 2029 at a Compound Annual Growth Rate (CAGR) of 12.8%. The projected growth during this period can be attributed to better healthcare access, the increasing rate of cancer, and a boosted demand for antisense and RNAi therapeutics, driven by COVID-19. The forecast period will see major trends such as concentrated research and development efforts for RNA therapeutics towards orphan diseases, the use of nanoparticles, the creation of improved and new antisense and RNAi therapeutics, and company collaborations for product innovation and revenue growth.

    Download a free sample to assess the report’s scope and structure:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=3389&type=smp

    Which Factors and External Forces Are Driving Demand in the Antisense & RNAi Therapeutics Market?

    The antisense & RNAi therapeutics market is anticipated to benefit from the growing occurrence of coronary artery diseases, neurodegenerative disorders, and infections. Approaches such as RNA interference and antisense oligonucleotides, which suppress gene expression, are utilized to treat a variety of neurodegenerative diseases by repairing defective genes. For example, a report from the American Heart Association, a US-based organization, stated in January 2024 that the age-adjusted death rate from heart-related illnesses had risen to 233.3 per 100,000, indicating a 4.0% increase from the preceding year. As a result, the rising incidences of numerous neurodegenerative disorders and infectious ailments are anticipated to stimulate the antisense & RNAi therapeutics market’s expansion.

    Which Segments in the Antisense & RNAi Therapeutics Offer the Most Growth?

    The antisense & rnai therapeutics market covered in this report is segmented –

    1) By Technology: RNA Interference, Antisense RNA

    2) By Route Of Administration: Intravenous Injections, Intra-dermal Injections, Other Delivery Methods

    3) By Indication: Oncology, Cardiovascular Diseases (CVDs), Respiratory Disorders, Neurological Disorders, Infectious Diseases, Other Indications

    Subsegments:

    1) By RNA Interference (RNAi): Small Interfering RNA (siRNA), Short Hairpin RNA (shRNA), Dicer-substrate siRNA, MicroRNA (miRNA) Based Therapeutics

    2) By Antisense RNA: Antisense Oligonucleotides (ASOs), Morpholino Oligomers, Locked Nucleic Acids (LNAs), Gapmer Antisense Oligonucleotides

    Request customized data on this market:

    https://www.thebusinessresearchcompany.com/customise?id=3389&type=smp

    What Are the Fastest-Growing Geographies in the #Which Factors and External Forces Are Driving Demand in the Antisense & RNAi Therapeutics Market?# Market?

    North America was the largest region in the antisense & RNAi therapeutics market in 2024. The regions covered in the antisense & RNAi therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

    Which Cutting-Edge Market Trends Are Expected to Drive theAntisense & RNAi Therapeutics Market’s Growth?

    Key players in the antisense & RNAi therapeutics market are embracing strategic actions like partnerships and collaborations to retain their competitiveness in the ever-tightening industry. The concept of strategic collaboration refers to several businesses pooling resources together to achieve shared goals. For instance, Orbit Discovery Limited, an American company that provides peptide discovery services, formed a partnership with SanegeneBio Inc., a UK-based firm that develops novel RNAi-based medicines, in January 2023. Their goal was to identify tissue-specific delivery of RNA therapeutics for efficient gene knockdown and consequently create a series of advanced RNAi therapeutics. The agreement included hit identification and cellular internalization studies, with Sanegene earning the option to advance the screened hits using Orbit’s distinctive technology for quick peptide lead discovery. Orbit Discovery’s exclusive peptide display technology allows the screening of enormous peptide libraries, thus facilitating faster discovery of suitable peptide leads through affinity and functionality screens.

    View the full report here:

    https://www.thebusinessresearchcompany.com/report/antisense-and-rnai-therapeutics-global-market-report

    What Are the Key Elements That Define the Antisense & RNAi Therapeutics Market?

    Antisense therapy refers to the selective, sequence-specific suppression of gene expression by single-stranded DNA oligonucleotides. Contrarily, RNA interference (RNAi) is activated by double-stranded RNA (dsRNA) and results in the sequence-specific mRNA degradation of single-stranded target RNAs.

    Purchase the full report and get a swift delivery:

    https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3389

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Europe +44 7882 955267

    Asia & Others +44 7882 955267 & +91 8897263534

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Antisense & RNAi Therapeutics Market Valuation Expected To Reach $3.11 Billion By 2029, Growing At A Rate Of 12.8%

    Antisense & RNAi Therapeutics Market Valuation Expected To Reach $3.11 Billion By 2029, Growing At A Rate Of 12.8%

    Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

    #How Has the Antisense & RNAi Therapeutics Market Growth Performance Trended Historically, And What Lies Ahead?#_x000D_

    The market size of antisense and RNAi therapeutics has experienced a swift upsurge in recent times, with projections showing an increase from $1.75 billion in 2024 to $1.93 billion in 2025, indicating a compound annual growth rate (CAGR) of 10.2%. This augmentation during the historical period can be ascribed to an upswing in funding, technological advancements, and an increase in health care spending, alongside a fast-paced growth in the aged population and the economic expansion in budding markets._x000D_

    _x000D_

    In the coming years, the antisense & RNAi therapeutics market is projected to experience substantial growth, expanding to $3.11 billion in 2029 at a Compound Annual Growth Rate (CAGR) of 12.8%. The projected growth during this period can be attributed to better healthcare access, the increasing rate of cancer, and a boosted demand for antisense and RNAi therapeutics, driven by COVID-19. The forecast period will see major trends such as concentrated research and development efforts for RNA therapeutics towards orphan diseases, the use of nanoparticles, the creation of improved and new antisense and RNAi therapeutics, and company collaborations for product innovation and revenue growth._x000D_

    _x000D_

    #Download a free sample to assess the report’s scope and structure:#_x000D_

    https://www.thebusinessresearchcompany.com/sample.aspx?id=3389&type=smp_x000D_

    _x000D_

    #Which Factors and External Forces Are Driving Demand in the Antisense & RNAi Therapeutics Market?#_x000D_

    The antisense & RNAi therapeutics market is anticipated to benefit from the growing occurrence of coronary artery diseases, neurodegenerative disorders, and infections. Approaches such as RNA interference and antisense oligonucleotides, which suppress gene expression, are utilized to treat a variety of neurodegenerative diseases by repairing defective genes. For example, a report from the American Heart Association, a US-based organization, stated in January 2024 that the age-adjusted death rate from heart-related illnesses had risen to 233.3 per 100,000, indicating a 4.0% increase from the preceding year. As a result, the rising incidences of numerous neurodegenerative disorders and infectious ailments are anticipated to stimulate the antisense & RNAi therapeutics market’s expansion._x000D_

    _x000D_

    #Which Segments in the Antisense & RNAi Therapeutics Offer the Most Growth?#_x000D_

    The antisense & rnai therapeutics market covered in this report is segmented – _x000D_

    _x000D_

    1) By Technology: RNA Interference, Antisense RNA_x000D_

    2) By Route Of Administration: Intravenous Injections, Intra-dermal Injections, Other Delivery Methods_x000D_

    3) By Indication: Oncology, Cardiovascular Diseases (CVDs), Respiratory Disorders, Neurological Disorders, Infectious Diseases, Other Indications_x000D_

    _x000D_

    Subsegments:_x000D_

    1) By RNA Interference (RNAi): Small Interfering RNA (siRNA), Short Hairpin RNA (shRNA), Dicer-substrate siRNA, MicroRNA (miRNA) Based Therapeutics _x000D_

    2) By Antisense RNA: Antisense Oligonucleotides (ASOs), Morpholino Oligomers, Locked Nucleic Acids (LNAs), Gapmer Antisense Oligonucleotides _x000D_

    _x000D_

    #Request customized data on this market:#_x000D_

    https://www.thebusinessresearchcompany.com/customise?id=3389&type=smp_x000D_

    _x000D_

    #What Are the Fastest-Growing Geographies in the #Which Factors and External Forces Are Driving Demand in the Antisense & RNAi Therapeutics Market?# Market?#_x000D_

    North America was the largest region in the antisense & RNAi therapeutics market in 2024. The regions covered in the antisense & RNAi therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa_x000D_

    _x000D_

    #Which Cutting-Edge Market Trends Are Expected to Drive theAntisense & RNAi Therapeutics Market’s Growth?#_x000D_

    Key players in the antisense & RNAi therapeutics market are embracing strategic actions like partnerships and collaborations to retain their competitiveness in the ever-tightening industry. The concept of strategic collaboration refers to several businesses pooling resources together to achieve shared goals. For instance, Orbit Discovery Limited, an American company that provides peptide discovery services, formed a partnership with SanegeneBio Inc., a UK-based firm that develops novel RNAi-based medicines, in January 2023. Their goal was to identify tissue-specific delivery of RNA therapeutics for efficient gene knockdown and consequently create a series of advanced RNAi therapeutics. The agreement included hit identification and cellular internalization studies, with Sanegene earning the option to advance the screened hits using Orbit’s distinctive technology for quick peptide lead discovery. Orbit Discovery’s exclusive peptide display technology allows the screening of enormous peptide libraries, thus facilitating faster discovery of suitable peptide leads through affinity and functionality screens._x000D_

    _x000D_

    #View the full report here:#_x000D_

    https://www.thebusinessresearchcompany.com/report/antisense-and-rnai-therapeutics-global-market-report_x000D_

    _x000D_

    #What Are the Key Elements That Define the Antisense & RNAi Therapeutics Market?#_x000D_

    Antisense therapy refers to the selective, sequence-specific suppression of gene expression by single-stranded DNA oligonucleotides. Contrarily, RNA interference (RNAi) is activated by double-stranded RNA (dsRNA) and results in the sequence-specific mRNA degradation of single-stranded target RNAs._x000D_

    _x000D_

    #Purchase the full report and get a swift delivery:#_x000D_

    https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3389_x000D_

    _x000D_

    #About The Business Research Company:#_x000D_

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

    _x000D_

    #Get in touch with us:#_x000D_

    The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

    Americas +1 310-496-7795_x000D_

    Europe +44 7882 955267_x000D_

    Asia & Others +44 7882 955267 & +91 8897263534_x000D_

    Email us at info@tbrc.info_x000D_

    _x000D_

    #Follow us on:#_x000D_

    _x000D_

    LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Key Developments and Trends Steering the Antisense & RNAi Therapeutics Market Forward: Strategic Collaborations Driving Innovation In The Antisense & RNAI Therapeutics Market

    Key Developments and Trends Steering the Antisense & RNAi Therapeutics Market Forward: Strategic Collaborations Driving Innovation In The Antisense & RNAI Therapeutics Market

    Discover trends, market shifts, and competitive outlooks for the antisense & rnai therapeutics industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

    #How Has The Antisense & RNAi Therapeutics Market Size Shifted, And What Is the Outlook Through 2034?

    The market for antisense & RNAi therapeutics has experienced quick expansion in recent years. Its size is expected to escalate from $1.75 billion in 2024 to $1.94 billion in 2025, with a compound annual growth rate (CAGR) of 11.2%. This increasing trend in the historic period can be traced back to increased funding, technological advancements, surge in healthcare spending, quick rise of the aging population, and economic progression in emerging markets.

    In the coming years, the antisense & RNAi therapeutics market is predicted to witness significant growth, reaching $3.18 billion by 2029 with a compound annual growth rate (CAGR) of 13.1%. This projected expansion during the forecast period could be credited to broader healthcare accessibility, an escalating incidence of cancer, and a growing demand for antisense and RNAi therapeutics triggered by the COVID-19 pandemic. The prediction period is likely to observe key trends including targeted research and development efforts for orphan disease RNA therapeutics, application of nanoparticles, invention of new and enhanced antisense and RNAi therapeutics, and partnerships with other corporations to brainstorm innovative products and boost revenue.

    Download a free sample to assess the report’s scope and structure:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=3389&type=smp

    How Are Key Drivers in the Industry Acting as Catalysts for the Growth of theAntisense & RNAi Therapeutics Market?

    The increasing incidence of conditions like coronary artery diseases, neurodegenerative disorders, and infectious diseases is expected to stimulate demand for the antisense & RNAi therapeutics market. Techniques that suppress genes, like RNA interference and antisense oligonucleotides, are employed to treat a range of neurodegenerative diseases by rectifying mutant genes. For instance, data from a report by the American Heart Association, a US-based entity, revealed that there was a rise to 233.3 per 100,000 in the age-adjusted death rate from cardiovascular diseases in January 2024, signifying a 4.0% increase from the preceding year. Consequently, the escalating prevalence of various neurodegenerative diseases and infectious diseases is anticipated to propel the growth of the antisense & RNAi therapeutics market.

    Which Segments in the Antisense & RNAi Therapeutics Offer the Most Growth?

    The antisense & RNAi therapeutics market covered in this report is segmented –

    1) By Technology: RNA Interference, Antisense RNA

    2) By Route Of Administration: Intravenous Injections, Intra-dermal Injections, Other Delivery Methods

    3) By Indication: Oncology, Cardiovascular Diseases (CVDs), Respiratory Disorders, Neurological Disorders, Infectious Diseases, Other Indications

    Subsegments:

    1) By RNA Interference (RNAi): Small Interfering RNA (siRNA), Short Hairpin RNA (shRNA), Dicer-substrate siRNA, MicroRNA (miRNA) Based Therapeutics

    2) By Antisense RNA: Antisense Oligonucleotides (ASOs), Morpholino Oligomers, Locked Nucleic Acids (LNAs), Gapmer Antisense Oligonucleotides

    Request customized data on this market:

    https://www.thebusinessresearchcompany.com/customise?id=3389&type=smp

    What Are the Fastest-Growing Geographies in the #How Are Key Drivers in the Industry Acting as Catalysts for the Growth of theAntisense & RNAi Therapeutics Market?# Market?

    North America was the largest region in the antisense & RNAi therapeutics market in 2024. The regions covered in the antisense & RNAi therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

    What Are the Current Market Growth and Trends in the Antisense & RNAi Therapeutics Industry?

    Large corporations involved in the antisense and RNAi therapeutics market are implementing strategic maneuvers like partnerships and collaborations to stay afloat in an intensifying competitive field. This business tactic requires at least two companies to work jointly towards a mutual goal. For instance, Orbit Discovery Limited, a company based in the US and specializing in the identification of peptides, formed a partnership with SanegeneBio Inc., a UK-based firm that is developing unique RNAi-based medicine. This partnership was initiated in January 2023 with the goal being to identify tissue-specific RNA therapeutics to enhance gene knockdown efficiency, subsequently contributing to the development of advanced RNAi therapeutics. Under this agreement, both companies will undertake hit identification and cell-based internalization studies, with Sanegene retaining the ability to further develop the identified potential hits using Orbit’s exclusive rapid peptide discovery technology. Orbit Discovery’s novel peptide display engine allows for large-scale peptide library screening, hastening the identification of relevant peptide leads using affinity and function screens.

    View the full report here:

    https://www.thebusinessresearchcompany.com/report/antisense-and-rnai-therapeutics-global-market-report

    What Are the Key Elements That Define the Antisense & RNAi Therapeutics Market?

    Antisense therapy refers to the selective, sequence-specific suppression of gene expression by single-stranded DNA oligonucleotides. Contrarily, RNA interference (RNAi) is activated by double-stranded RNA (dsRNA) and results in the sequence-specific mRNA degradation of single-stranded target RNAs.

    Purchase the full report and get a swift delivery:

    https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3389

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 3156230293

    Asia +44 2071930708

    Europe +44 2071930708

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Antisense & RNAi Therapeutics Market Growth and Trends: Key Insights into Market Opportunities for 2025-2034

    Antisense & RNAi Therapeutics Market Growth and Trends: Key Insights into Market Opportunities for 2025-2034

    2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

    How Are Key Drivers in the Industry Acting as Catalysts for the Growth of theAntisense & RNAi Therapeutics Market?

    The increasing incidences of coronary artery diseases, neurodegenerative conditions, and infectious diseases are expected to fuel the demand in the antisense & RNAi therapeutics market. Gene silencing techniques, such as RNA interference and antisense oligonucleotides, are employed for treating a variety of neurodegenerative diseases by fixing faulty genes. For example, as per the American Heart Association’s report in January 2024, a US-based entity, the age-adjusted death rate due to cardiovascular diseases rose to 233.3 per 100,000, marking a 4.0% increase from the previous year. Consequently, the rising occurrence of numerous neurodegenerative and infectious diseases is predicted to propel the antisense & RNAi therapeutics market’s growth.

    Get Your Free Sample Report Now – Explore Exclusive Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=3389&type=smp

    #What Long-Term Growth Rate is Expected for theAntisense & RNAi Therapeutics Market Between 2025 and 2034?

    The dimension of the antisense & RNAi therapeutics market has seen swift expansion in the recent past. The market, which stands at $1.75 billion in 2024, is projected to elevate to $1.94 billion in 2025, showing a compound annual growth rate (CAGR) of 11.2%. The historical growth trajectory is tied to factors such as an upsurge in funding, technological advances, an increase in healthcare spending, a fast-rising aged population, and the economic advancement of emerging markets.

    The market size of antisense & RNAi therapeutics is projected to witness substantial growth in the coming years. The market is estimated to balloon to $3.18 billion in 2029 with a compound annual growth rate (CAGR) of 13.1%. The expected growth during the forecast period is due to factors such as increased access to healthcare, a rise in cancer cases, and a growing demand for antisense and RNAi therapeutics amid the COVID-19 pandemic. Key trends during the forecast period will mainly center on the dedicated research and development of RNA therapeutics for rare diseases, adoption of nanoparticles, advancement of novel and enhanced antisense and RNAi therapeutics, and strategic partnerships with other firms to foster product innovation and revenue growth.

    You can Directly Purchase the Report Here:

    https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3389

    What Are the Current Market Growth and Trends in theAntisense & RNAi Therapeutics Market That Industry Players Should Watch?

    Prominent corporations engaged in the antisense & RNAi therapeutics market are adopting strategic measures such as collaborations and alliances to remain viable in the escalating competitive environment. Strategic collaborations consist of two or more organizations collaboratively working on a shared aim or objective. For instance, in January 2023, a partnership was forged between Orbit Discovery Limited, a U.S.-based provider of peptide discovery services, and SanegeneBio Inc., a U.K.-based corporation focused on creating innovative RNAi-based drugs, to aid in the identification of tissue-specific delivery of RNA therapeutics for efficient gene knockdown, with the end goal of crafting a range of advanced RNAi therapeutics. This partnership includes hit identification and internalization studies using cells, with SanegeneBio acquiring the privilege to further refine hits garnered from the screening procedures, optimized using Orbit’s exclusive technology designed for swift peptide lead discovery. Orbit Discovery’s distinct peptide display engine facilitates screening of sizable peptide libraries, thus expediting the discovery of suitable peptide leads based on affinity and functional screens.

    What Are the Major Market Players Making an Impact on theAntisense & RNAi Therapeutics Market Growth?

    Major companies operating in the antisense & RNAi therapeutics market include Biogen Inc., Ionis Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Moderna Inc., Sanofi S.A., Dicerna Pharmaceuticals Inc., Arbutus Biopharma Corporation, Acuitas Therapeutics, Adhera Therapeutics Inc., EdiGene Inc., Sirnaomics Inc., Suzhou Ribo Life Science Co. Ltd, Biocon Limited, Quark Pharmaceuticals, GlaxoSmithKline Plc, Shanghai Junshi Biosciences Co. Ltd., AstraZeneca, Benitec Biopharma Limited, Silence Therapeutics, Dynacure, CN Bio Innovations, Sarepta Therapeutics, Mallinckrodt, Regeneron Pharmaceuticals Inc., Alcyone Lifesciences Inc., Bio-Path Holdings Inc, Calando Pharmaceuticals, Enzon Pharmaceuticals Inc, Celnova Pharma, Pfizer Inc., Taiba Pharma, Gen Ilaç ve Saglik Ürünleri A.S., Egypt Otsuka Pharmaceutical

    Order Your Report Now For A Swift Delivery:

    https://www.thebusinessresearchcompany.com/report/antisense-and-rnai-therapeutics-global-market-report

    How Are the Key Segments of the Antisense & RNAi Therapeutics Market Driving Opportunities and Innovations?

    The antisense & RNAi therapeutics market covered in this report is segmented –

    1) By Technology: RNA Interference, Antisense RNA

    2) By Route Of Administration: Intravenous Injections, Intra-dermal Injections, Other Delivery Methods

    3) By Indication: Oncology, Cardiovascular Diseases (CVDs), Respiratory Disorders, Neurological Disorders, Infectious Diseases, Other Indications

    Subsegments:

    1) By RNA Interference (RNAi): Small Interfering RNA (siRNA), Short Hairpin RNA (shRNA), Dicer-substrate siRNA, MicroRNA (miRNA) Based Therapeutics

    2) By Antisense RNA: Antisense Oligonucleotides (ASOs), Morpholino Oligomers, Locked Nucleic Acids (LNAs), Gapmer Antisense Oligonucleotides

    Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

    https://www.thebusinessresearchcompany.com/customise?id=3389&type=smp

    What Regions Are At the Forefront of #How Are Key Drivers in the Industry Acting as Catalysts for the Growth of theAntisense & RNAi Therapeutics Market?# Market Expansion?

    North America was the largest region in the antisense & RNAi therapeutics market in 2024. The regions covered in the antisense & RNAi therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

    Browse Through More Reports Similar to the Global Antisense & RNAi Therapeutics Market 2025, By The Business Research Company:

    Anti-Hypertensive Drugs Global Market Report 2024

    https://www.thebusinessresearchcompany.com/report/anti-hypertensive-drugs-global-market-report

    Neurodegenerative Disorder Therapeutics Global Market Report 2024

    https://www.thebusinessresearchcompany.com/report/neurodegenerative-disorder-therapeutic-global-market-report

    Biosimilar Hormones Global Market Report 2024

    https://www.thebusinessresearchcompany.com/report/biosimilar-hormone-global-market-report

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Contact us at:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 3156230293

    Asia +44 2071930708

    Europe +44 2071930708

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

    Found this article helpful? Share it on:

  • Future Outlook of the Antisense & RNAi Therapeutics Market: Growth, Trends, and Emerging Opportunities Explored

    Future Outlook of the Antisense & RNAi Therapeutics Market: Growth, Trends, and Emerging Opportunities Explored

    Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

    What is the Expected Growth Rate of the Antisense & RNAi Therapeutics Market Based on Industry Projections?

    The antisense & RNAi therapeutics market has grown rapidly. It is forecasted to rise from $1.75 billion in 2024 to $1.94 billion in 2025, reflecting a CAGR of 11.2%. Growth has been driven by increased research funding, advancements in technology, rising healthcare expenditure, an aging population, and economic expansion in emerging markets.

    The antisense & RNAi therapeutics market is expected to witness rapid growth in the next few years, projected to reach $3.18 billion by 2029 at a compound annual growth rate (CAGR) of 13.1%. The growth during this period can be attributed to increased healthcare access, rising cancer prevalence, and growing demand for antisense and RNAi therapeutics in response to COVID-19. Major trends expected in the forecast period include research and development focused on RNA therapeutics for orphan diseases, the use of nanoparticles, the development of improved antisense and RNAi therapeutics, and collaborations with other companies for product innovation and revenue generation.

    Which Macro and Microeconomic Factors Are Accelerating the Growth of the antisense & rnai therapeutics Market?

    The rising prevalence of coronary artery diseases, neurodegenerative disorders, and infectious diseases is expected to drive the antisense & RNAi therapeutics market. RNA interference and antisense oligonucleotides are gene-suppressing treatments used to address various neurodegenerative conditions. According to the American Heart Association, the age-adjusted death rate from cardiovascular diseases increased to 233.3 per 100,000 in January 2024, showing a 4.0% rise from the previous year. Consequently, the growing number of neurodegenerative diseases and infectious diseases will contribute to the demand for antisense & RNAi therapeutics.

    Request Your Free Antisense & RNAi Therapeutics Market Report Sample Now!

    https://www.thebusinessresearchcompany.com/sample.aspx?id=3389&type=smp

    What Companies Are At the Forefront of Innovation in the Antisense & RNAi Therapeutics Market?

    Major companies operating in the antisense & RNAi therapeutics market include:

    • Biogen Inc._x000D_

    • Ionis Pharmaceuticals Inc._x000D_

    • Alnylam Pharmaceuticals Inc._x000D_

    • Arrowhead Pharmaceuticals Inc._x000D_

    • Moderna Inc._x000D_

    How Are Emerging Trends in Consumer Behavior Affecting the Antisense & RNAi Therapeutics Market?

    Key players in the antisense and RNAi therapeutics market are forming strategic collaborations and partnerships to stay competitive. A strategic collaboration involves multiple companies working together to achieve shared goals. For example, in January 2023, Orbit Discovery Limited, a US-based peptide discovery company, partnered with SanegeneBio Inc., a UK-based developer of RNAi-based medicines. This collaboration focuses on identifying tissue-specific delivery mechanisms for RNA therapeutics to enhance gene knockdown efficiency. The partnership includes hit identification and cell-based internalization studies, allowing Sanegene to advance potential candidates using Orbit’s proprietary peptide discovery technology. Orbit’s platform enables rapid screening of large peptide libraries, expediting lead identification through affinity and functional screens.

    Pre-order Your Report for Quick and Easy Delivery!

    https://www.thebusinessresearchcompany.com/report/antisense-and-rnai-therapeutics-global-market-report

    Which Segments Play a Crucial Role in the Expansion of the Antisense & RNAi Therapeutics Market?

    The antisense & RNAi therapeutics market covered in this report is segmented –

    1) By Technology: RNA Interference, Antisense RNA

    2) By Route Of Administration: Intravenous Injections, Intra-dermal Injections, Other Delivery Methods

    3) By Indication: Oncology, Cardiovascular Diseases (CVDs), Respiratory Disorders, Neurological Disorders, Infectious Diseases, Other Indications

    Subsegments:

    1) By RNA Interference (RNAi): Small Interfering RNA (siRNA), Short Hairpin RNA (shRNA), Dicer-substrate siRNA, MicroRNA (miRNA) Based Therapeutics

    2) By Antisense RNA: Antisense Oligonucleotides (ASOs), Morpholino Oligomers, Locked Nucleic Acids (LNAs), Gapmer Antisense Oligonucleotides

    What Regions Are Propelling Growth in the Antisense & RNAi Therapeutics Industry?

    North America was the largest region in the antisense & RNAi therapeutics market in 2024. The regions covered in the antisense & RNAi therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

    How Is the Antisense & RNAi Therapeutics Market Categorized and Defined in the Industry?

    Antisense therapy refers to the selective, sequence-specific suppression of gene expression by single-stranded DNA oligonucleotides. Contrarily, RNA interference (RNAi) is activated by double-stranded RNA (dsRNA) and results in the sequence-specific mRNA degradation of single-stranded target RNAs.

    Browse Through More Similar Reports By The Business Research Company:

    Anti-Hypertensive Drugs Global Market Report 2024

    https://www.thebusinessresearchcompany.com/report/anti-hypertensive-drugs-global-market-report

    Neurodegenerative Disorder Therapeutics Global Market Report 2024

    https://www.thebusinessresearchcompany.com/report/neurodegenerative-disorder-therapeutic-global-market-report

    Biosimilar Hormones Global Market Report 2024

    https://www.thebusinessresearchcompany.com/report/biosimilar-hormone-global-market-report

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Contact us at:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 3156230293

    Asia +44 2071930708

    Europe +44 2071930708

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

    Found this article helpful? Share it on:

  • Future Outlook of the Antisense & RNAi Therapeutics Market: Growth, Trends, and Emerging Opportunities Explored

    Future Outlook of the Antisense & RNAi Therapeutics Market: Growth, Trends, and Emerging Opportunities Explored

    Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

    What is the Expected Growth Rate of the Antisense & RNAi Therapeutics Market Based on Industry Projections?

    The antisense & RNAi therapeutics market has grown rapidly. It is forecasted to rise from $1.75 billion in 2024 to $1.94 billion in 2025, reflecting a CAGR of 11.2%. Growth has been driven by increased research funding, advancements in technology, rising healthcare expenditure, an aging population, and economic expansion in emerging markets.

    The antisense & RNAi therapeutics market is expected to witness rapid growth in the next few years, projected to reach $3.18 billion by 2029 at a compound annual growth rate (CAGR) of 13.1%. The growth during this period can be attributed to increased healthcare access, rising cancer prevalence, and growing demand for antisense and RNAi therapeutics in response to COVID-19. Major trends expected in the forecast period include research and development focused on RNA therapeutics for orphan diseases, the use of nanoparticles, the development of improved antisense and RNAi therapeutics, and collaborations with other companies for product innovation and revenue generation.

    Which Macro and Microeconomic Factors Are Accelerating the Growth of the antisense & rnai therapeutics Market?

    The rising prevalence of coronary artery diseases, neurodegenerative disorders, and infectious diseases is expected to drive the antisense & RNAi therapeutics market. RNA interference and antisense oligonucleotides are gene-suppressing treatments used to address various neurodegenerative conditions. According to the American Heart Association, the age-adjusted death rate from cardiovascular diseases increased to 233.3 per 100,000 in January 2024, showing a 4.0% rise from the previous year. Consequently, the growing number of neurodegenerative diseases and infectious diseases will contribute to the demand for antisense & RNAi therapeutics.

    Request Your Free Antisense & RNAi Therapeutics Market Report Sample Now!

    https://www.thebusinessresearchcompany.com/sample.aspx?id=3389&type=smp

    What Companies Are At the Forefront of Innovation in the Antisense & RNAi Therapeutics Market?

    Major companies operating in the antisense & RNAi therapeutics market include:

    • Biogen Inc._x000D_

    • Ionis Pharmaceuticals Inc._x000D_

    • Alnylam Pharmaceuticals Inc._x000D_

    • Arrowhead Pharmaceuticals Inc._x000D_

    • Moderna Inc._x000D_

    How Are Emerging Trends in Consumer Behavior Affecting the Antisense & RNAi Therapeutics Market?

    Key players in the antisense and RNAi therapeutics market are forming strategic collaborations and partnerships to stay competitive. A strategic collaboration involves multiple companies working together to achieve shared goals. For example, in January 2023, Orbit Discovery Limited, a US-based peptide discovery company, partnered with SanegeneBio Inc., a UK-based developer of RNAi-based medicines. This collaboration focuses on identifying tissue-specific delivery mechanisms for RNA therapeutics to enhance gene knockdown efficiency. The partnership includes hit identification and cell-based internalization studies, allowing Sanegene to advance potential candidates using Orbit’s proprietary peptide discovery technology. Orbit’s platform enables rapid screening of large peptide libraries, expediting lead identification through affinity and functional screens.

    Pre-order Your Report for Quick and Easy Delivery!

    https://www.thebusinessresearchcompany.com/report/antisense-and-rnai-therapeutics-global-market-report

    Which Segments Play a Crucial Role in the Expansion of the Antisense & RNAi Therapeutics Market?

    The antisense & RNAi therapeutics market covered in this report is segmented –

    1) By Technology: RNA Interference, Antisense RNA

    2) By Route Of Administration: Intravenous Injections, Intra-dermal Injections, Other Delivery Methods

    3) By Indication: Oncology, Cardiovascular Diseases (CVDs), Respiratory Disorders, Neurological Disorders, Infectious Diseases, Other Indications

    Subsegments:

    1) By RNA Interference (RNAi): Small Interfering RNA (siRNA), Short Hairpin RNA (shRNA), Dicer-substrate siRNA, MicroRNA (miRNA) Based Therapeutics

    2) By Antisense RNA: Antisense Oligonucleotides (ASOs), Morpholino Oligomers, Locked Nucleic Acids (LNAs), Gapmer Antisense Oligonucleotides

    What Regions Are Propelling Growth in the Antisense & RNAi Therapeutics Industry?

    North America was the largest region in the antisense & RNAi therapeutics market in 2024. The regions covered in the antisense & RNAi therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

    How Is the Antisense & RNAi Therapeutics Market Categorized and Defined in the Industry?

    Antisense therapy refers to the selective, sequence-specific suppression of gene expression by single-stranded DNA oligonucleotides. Contrarily, RNA interference (RNAi) is activated by double-stranded RNA (dsRNA) and results in the sequence-specific mRNA degradation of single-stranded target RNAs.

    Browse Through More Similar Reports By The Business Research Company:

    Anti-Hypertensive Drugs Global Market Report 2024

    https://www.thebusinessresearchcompany.com/report/anti-hypertensive-drugs-global-market-report

    Neurodegenerative Disorder Therapeutics Global Market Report 2024

    https://www.thebusinessresearchcompany.com/report/neurodegenerative-disorder-therapeutic-global-market-report

    Biosimilar Hormones Global Market Report 2024

    https://www.thebusinessresearchcompany.com/report/biosimilar-hormone-global-market-report

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Contact us at:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 3156230293

    Asia +44 2071930708

    Europe +44 2071930708

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

    Found this article helpful? Share it on:

  • Future Outlook of the Antisense & RNAi Therapeutics Market: Growth, Trends, and Emerging Opportunities Explored

    Future Outlook of the Antisense & RNAi Therapeutics Market: Growth, Trends, and Emerging Opportunities Explored

    Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

    What is the Expected Growth Rate of the Antisense & RNAi Therapeutics Market Based on Industry Projections?

    The antisense & RNAi therapeutics market has grown rapidly. It is forecasted to rise from $1.75 billion in 2024 to $1.94 billion in 2025, reflecting a CAGR of 11.2%. Growth has been driven by increased research funding, advancements in technology, rising healthcare expenditure, an aging population, and economic expansion in emerging markets.

    The antisense & RNAi therapeutics market is expected to witness rapid growth in the next few years, projected to reach $3.18 billion by 2029 at a compound annual growth rate (CAGR) of 13.1%. The growth during this period can be attributed to increased healthcare access, rising cancer prevalence, and growing demand for antisense and RNAi therapeutics in response to COVID-19. Major trends expected in the forecast period include research and development focused on RNA therapeutics for orphan diseases, the use of nanoparticles, the development of improved antisense and RNAi therapeutics, and collaborations with other companies for product innovation and revenue generation.

    Which Macro and Microeconomic Factors Are Accelerating the Growth of the antisense & rnai therapeutics Market?

    The rising prevalence of coronary artery diseases, neurodegenerative disorders, and infectious diseases is expected to drive the antisense & RNAi therapeutics market. RNA interference and antisense oligonucleotides are gene-suppressing treatments used to address various neurodegenerative conditions. According to the American Heart Association, the age-adjusted death rate from cardiovascular diseases increased to 233.3 per 100,000 in January 2024, showing a 4.0% rise from the previous year. Consequently, the growing number of neurodegenerative diseases and infectious diseases will contribute to the demand for antisense & RNAi therapeutics.

    Request Your Free Antisense & RNAi Therapeutics Market Report Sample Now!

    https://www.thebusinessresearchcompany.com/sample.aspx?id=3389&type=smp

    What Companies Are At the Forefront of Innovation in the Antisense & RNAi Therapeutics Market?

    Major companies operating in the antisense & RNAi therapeutics market include:

    • Biogen Inc._x000D_

    • Ionis Pharmaceuticals Inc._x000D_

    • Alnylam Pharmaceuticals Inc._x000D_

    • Arrowhead Pharmaceuticals Inc._x000D_

    • Moderna Inc._x000D_

    How Are Emerging Trends in Consumer Behavior Affecting the Antisense & RNAi Therapeutics Market?

    Key players in the antisense and RNAi therapeutics market are forming strategic collaborations and partnerships to stay competitive. A strategic collaboration involves multiple companies working together to achieve shared goals. For example, in January 2023, Orbit Discovery Limited, a US-based peptide discovery company, partnered with SanegeneBio Inc., a UK-based developer of RNAi-based medicines. This collaboration focuses on identifying tissue-specific delivery mechanisms for RNA therapeutics to enhance gene knockdown efficiency. The partnership includes hit identification and cell-based internalization studies, allowing Sanegene to advance potential candidates using Orbit’s proprietary peptide discovery technology. Orbit’s platform enables rapid screening of large peptide libraries, expediting lead identification through affinity and functional screens.

    Pre-order Your Report for Quick and Easy Delivery!

    https://www.thebusinessresearchcompany.com/report/antisense-and-rnai-therapeutics-global-market-report

    Which Segments Play a Crucial Role in the Expansion of the Antisense & RNAi Therapeutics Market?

    The antisense & RNAi therapeutics market covered in this report is segmented –

    1) By Technology: RNA Interference, Antisense RNA

    2) By Route Of Administration: Intravenous Injections, Intra-dermal Injections, Other Delivery Methods

    3) By Indication: Oncology, Cardiovascular Diseases (CVDs), Respiratory Disorders, Neurological Disorders, Infectious Diseases, Other Indications

    Subsegments:

    1) By RNA Interference (RNAi): Small Interfering RNA (siRNA), Short Hairpin RNA (shRNA), Dicer-substrate siRNA, MicroRNA (miRNA) Based Therapeutics

    2) By Antisense RNA: Antisense Oligonucleotides (ASOs), Morpholino Oligomers, Locked Nucleic Acids (LNAs), Gapmer Antisense Oligonucleotides

    What Regions Are Propelling Growth in the Antisense & RNAi Therapeutics Industry?

    North America was the largest region in the antisense & RNAi therapeutics market in 2024. The regions covered in the antisense & RNAi therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

    How Is the Antisense & RNAi Therapeutics Market Categorized and Defined in the Industry?

    Antisense therapy refers to the selective, sequence-specific suppression of gene expression by single-stranded DNA oligonucleotides. Contrarily, RNA interference (RNAi) is activated by double-stranded RNA (dsRNA) and results in the sequence-specific mRNA degradation of single-stranded target RNAs.

    Browse Through More Similar Reports By The Business Research Company:

    Anti-Hypertensive Drugs Global Market Report 2024

    https://www.thebusinessresearchcompany.com/report/anti-hypertensive-drugs-global-market-report

    Neurodegenerative Disorder Therapeutics Global Market Report 2024

    https://www.thebusinessresearchcompany.com/report/neurodegenerative-disorder-therapeutic-global-market-report

    Biosimilar Hormones Global Market Report 2024

    https://www.thebusinessresearchcompany.com/report/biosimilar-hormone-global-market-report

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Contact us at:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 3156230293

    Asia +44 2071930708

    Europe +44 2071930708

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

    Found this article helpful? Share it on:

  • Key Trends and Insights into the Antisense & RNAi Therapeutics Market: Growth Rate and Opportunities to 2034

    Key Trends and Insights into the Antisense & RNAi Therapeutics Market: Growth Rate and Opportunities to 2034

    Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

    How has the antisense & rnai therapeutics market size evolved in recent years?

    The market size for antisense & RNAi therapeutics has seen a swift expansion in the preceding years. The market, valued at $1.75 billion in 2024, is expected to increase to $1.94 billion in 2025 with a compound annual growth rate (CAGR) of 11.2%. This considerable growth during the previous time can be credited to factors such as increased funding, technological advancements, a surge in healthcare spending, a rapidly aging population, and economic growth in newly marketable areas.

    What are the predictions for the antisense & rnai therapeutics market size in the coming years?

    The market size of antisense & RNAi therapeutics is set to experience a rapid expansion in the coming years. It’s projected to reach $3.18 billion by 2029, with a Compound Annual Growth Rate (CAGR) of 13.1%. This predicted growth during the forecast period is largely due to increased access to healthcare, an escalating prevalence of cancer and the heightened need for antisense and RNAi therapeutics amidst the COVID-19 crisis. The forecast period will also see key trends such as intensified research and development into RNA therapeutics for rare diseases, the adoption of nanoparticles, the invention of advanced antisense and RNAi therapeutics, and strategic collaborations with different companies for product evolution and revenue growth.

    Get your antisense & rnai therapeutics market report here!

    https://www.thebusinessresearchcompany.com/report/antisense-and-rnai-therapeutics-global-market-report

    What key factors are fueling the growth of the antisense & rnai therapeutics market?

    The escalating incidences of coronary artery diseases, infectious diseases, and neurodegenerative disorders are anticipated to fuel the demand in the antisense & RNAi therapeutics market. Various neurodegenerative ailments are treated using gene suppression techniques such as RNA interference and antisense oligonucleotides, which help repair mutant genes. For example, a report released by the American Heart Association, an organization based in the US, illustrated that, in January 2024, the age-adjusted mortality rate from cardiovascular diseases rose by 4.0% from the past year, reaching 233.3 per 100,000 people. Hence, as the pervasiveness of numerous neurodegenerative and infectious diseases increases, so too is the antisense & RNAi therapeutics market projected to grow.

    How is the global antisense & rnai therapeutics market divided into key segments?

    The antisense & RNAi therapeutics market covered in this report is segmented –

    1) By Technology: RNA Interference, Antisense RNA

    2) By Route Of Administration: Intravenous Injections, Intra-dermal Injections, Other Delivery Methods

    3) By Indication: Oncology, Cardiovascular Diseases (CVDs), Respiratory Disorders, Neurological Disorders, Infectious Diseases, Other Indications

    Subsegments:

    1) By RNA Interference (RNAi): Small Interfering RNA (siRNA), Short Hairpin RNA (shRNA), Dicer-substrate siRNA, MicroRNA (miRNA) Based Therapeutics

    2) By Antisense RNA: Antisense Oligonucleotides (ASOs), Morpholino Oligomers, Locked Nucleic Acids (LNAs), Gapmer Antisense Oligonucleotides

    Get your free sample now – explore exclusive market insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=3389&type=smp

    Who are the key firms paving the way for growth in the antisense & rnai therapeutics market?

    Major companies operating in the antisense & RNAi therapeutics market include Biogen Inc., Ionis Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Moderna Inc., Sanofi S.A., Dicerna Pharmaceuticals Inc., Arbutus Biopharma Corporation, Acuitas Therapeutics, Adhera Therapeutics Inc., EdiGene Inc., Sirnaomics Inc., Suzhou Ribo Life Science Co. Ltd, Biocon Limited, Quark Pharmaceuticals, GlaxoSmithKline Plc, Shanghai Junshi Biosciences Co. Ltd., AstraZeneca, Benitec Biopharma Limited, Silence Therapeutics, Dynacure, CN Bio Innovations, Sarepta Therapeutics, Mallinckrodt, Regeneron Pharmaceuticals Inc., Alcyone Lifesciences Inc., Bio-Path Holdings Inc, Calando Pharmaceuticals, Enzon Pharmaceuticals Inc, Celnova Pharma, Pfizer Inc., Taiba Pharma, Gen Ilaç ve Saglik Ürünleri A.S., Egypt Otsuka Pharmaceutical

    Which trends are expected to transform the antisense & rnai therapeutics market?

    Leading enterprises in the antisense & RNAi therapeutics market are initiating strategic measures, including alliances and partnerships, to maintain their position in an intensifying market. This tactical collaboration involves cooperation between two or more firms to meet a aligned goal. For example, in January 2023, Orbit Discovery Limited, an American company that offers peptide discovery services, collaborated with UK-based SanegeneBio Inc., which develops original RNAi-based medication. This partnership aims to identify tissue-specific delivery of RNA therapies for effective gene knockdown, with an objective to formulate a collection of advanced RNAi therapeutics. The alliance includes the identification of potential therapeutic targets and cell-based internalization studies. Sanegene has the choice to further advance these potential targets identified from the screening activities, utilizing Orbit’s unique technology for quick peptide lead discovery. Orbit Discovery’s exclusive peptide display platform allows the analysis of expansive peptide libraries, ultimately leading to the faster discovery of significant peptide leads through affinity and functional screens.

    Unlock exclusive market insights – purchase your research report now for a swift delivery!

    https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3389

    What regions are contributing significantly to the growth of the antisense & rnai therapeutics market?

    North America was the largest region in the antisense & RNAi therapeutics market in 2024. The regions covered in the antisense & RNAi therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

    Browse Through More Similar Reports By The Business Research Company:

    Anti-Hypertensive Drugs Global Market Report 2024

    https://www.thebusinessresearchcompany.com/report/anti-hypertensive-drugs-global-market-report

    Neurodegenerative Disorder Therapeutics Global Market Report 2024

    https://www.thebusinessresearchcompany.com/report/neurodegenerative-disorder-therapeutic-global-market-report

    Biosimilar Hormones Global Market Report 2024

    https://www.thebusinessresearchcompany.com/report/biosimilar-hormone-global-market-report

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Contact us at:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 3156230293

    Asia +44 2071930708

    Europe +44 2071930708

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

    Found this article helpful? Share it on: